Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

OBJECTIVES: To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in patients with rheumatoid arthritis (RA) for an additional six infusions. METHODS: This open-label extension study recr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Dae Hyun, Prodanovic, Nenad, Jaworski, Janusz, Miranda, Pedro, Ramiterre, Edgar, Lanzon, Allan, Baranauskaite, Asta, Wiland, Piotr, Abud-Mendoza, Carlos, Oparanov, Boycho, Smiyan, Svitlana, Kim, HoUng, Lee, Sang Joon, Kim, SuYeon, Park, Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5284338/
https://www.ncbi.nlm.nih.gov/pubmed/27130908
http://dx.doi.org/10.1136/annrheumdis-2015-208786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5284338/
https://www.ncbi.nlm.nih.gov/pubmed/27130908
http://dx.doi.org/10.1136/annrheumdis-2015-208786

Ejemplares similares